Cytotoxic and Antitumor Activity of a Recombinant Tumor Necrosis Factor-B1(Fv) Fusion Protein on LeY Antigen-expressing Human Cancer Cells

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1523-1531

  Scherf, Uwe ^a   Benhar, Itai ^a,b   Webber, Keith O ^a   Pastan, Ira ^a   Brinkmann, Ulrich ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN FRAGMENT; LEWIS Y ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BIOSYNTHESIS; BLOOD GROUP LEWIS SYSTEM; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CYTOTOXICITY; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; MOUSE; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; PLASMID; XENOGRAFT;

ANIMALS; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LEWIS BLOOD-GROUP SYSTEM; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; PLASMIDS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030223024     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Laster, S. M., Wood, J. G., and Gooding, L. R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol., 141: 2629-2634, 1988.
2. Creaven, P. J., Plager, J. E., Dupere, S., Huben, R. P., Takita, H., Mittelman, A., and Proefrock, A. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol., 20: 137-144, 1987.
3. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T., and Parkinson, D. R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79: 2547-2554, 1992.
4. Brinkmann, U., and Pastan, I. Immunotoxins against cancer. Biochim. Biophys. Acta, 1198: 27-45, 1994.
5. Pastan, I., Pai, L. H., Brinkmann, U., and FitzGerald, D. J Recombinant toxins: new therapeutic agents for cancer. Ann. NY Acad. Sci., 758: 345-354, 1995.
6. Pastan, I., Lovelace, E. T., Gallo, M. G., Rutherford, A. V., Magnani, J. L., and Willingham, M. C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res., 51: 3781-3787, 1991.
7. Benhar, I., and Pastan, I. Cloning expression and characterization of the Fv fragments of the anticarbohydrate monoclonal antibodies B1 and B5 as single-chain immunotoxins. Protein Eng., 7: 1509-1515, 1995.
8. Kreitman, R. J., Puri, R. K., Leland, P., Lee, B., and Pastan, I. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity. Biochemistry, 33. 11637-11644, 1994.
9. Rosenblum, M. G., Cheung, L., Mujoo, K., and Murray, J. L. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol. Immunother., 40: 322-328, 1995.
10. Hoogenboom, H. R., Volckaert, G., and Raus, J. C. M. Construction and expression of antibody-tumor necrosis factor fusion proteins. Mol. Immunol., 28: 1027-1037, 1991.
11. Yang, J., Moyana, T., and Xiang, J. A genetically engineered single-chain Fv/TNF molecule possesses the anti-tumor immunoreactivity of Fv as well as the cytotoxic activity of tumor necrosis factor. Mol. Immunol., 32: 873-881, 1995
12. Gillies, S. D., Young, D., Lo, K-M., Foley, S. F., and Reisfeld, R. A Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma, 10: 347-356, 1991.
13. Gillies, S. D , Young, D., Lo, K-M., and Roberts, S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjugate Chem., 4: 230-235, 1993.
14. Rosenblum, M. G., Cheung, L., Murray, J. L., and Bartholomew, R. Antibody-mediated delivery of tumor necrosis factor (TNF-α): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun., 3: 21-27, 1991.
15. Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52: 3402-3408, 1992.
16. Sung, C., Dedrick, R. L., Hall, W. A., Johnson, P. A., and Youle, R. J. The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography. Cancer Res., 53: 2092-2099, 1993.
17. Brinkmann, U., and Pastan, I. Recombinant immunotoxins: from basic research to cancer therapy. Methods Enzymol., 8: 143-156, 1995.
18. Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M., Pastan, I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl Acad. Sci. USA, 88: 8616-8620, 1991.
19. Kunkel, T. A. Rapid and efficient site-directed mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA, 82: 488-492, 1985.
20. Studier, F. W., and Moffatt, B. A. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol Biol., 189: 113-130, 1986.
21. Buchner, J., Pastan, I., and Brinkmann, U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem., 205: 263-270, 1992.
22. Crowe, J., Dobeli, H., Gentz, R., Hochuli, E., Stuber, D., and Henco, K. 6xHis-Ni-NTA chromatography as a superior technique in recombinant protein expression/purification. Methods Mol. Biol., 31: 371-387, 1994.
23. Webber, K. O., Reiter, Y., Brinkmann, U., Kreitman, R., and Pastan, I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol., 32: 249-258, 1995.
24. Pai, L. H., Batra, J. K , FitzGerald, D. J., Willingham, M. C., and Pastan, I. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res., 52: 3189-3193, 1992.
25. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., and Goeddel, D. V. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (Lond.), 312: 724-729, 1984.
26. Sidhu, R. S., and Bollon, A. P. Tumor necrosis factor analogs: identification of functional domains. Anticancer Res, 9: 1569-1576, 1989.
27. Vassalli, P. The pathophysiology of tumor necrosis factor. Annu. Rev Immunol., 10: 411-452, 1992.
28. Qin, Z., van Tits, L. J. H., Buurman, W. A., and Blankenstein, T. Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice. Blood, 85: 2779-2785, 1995
29. Qin, Z., and Blankenstein, T. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Cancer Res., 55: 4747-4751, 1995.
30. Morimoto, H., and Bonavida, B. Diptheria toxin and Pseudomonas A toxin mediated apoptosis. ADP-ribosylation and elongation factor-2is required for DNA fragmentation and cell lysis and synergy with tumor factor α J. Immunol., 149: 2089-2094, 1992.
31. Brinkmann, U., Brinkmann, E., Gallo, M., Scherf, U., and Pastan, I. Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1 in toxin and tumor necrosis factor mediated apoptosis. Biochemistry, 35. 6891-6899, 1996.
32. Smith, R. A., and Baglioni, C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem., 262. 6951-6954, 1987.
33. Decker, T., Lohmann-Matthes, M. L., and Gifford, G. E. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J. Immunol, 138: 957-962, 1987.
34. Smith, M. R., Munger, W. E., Kung, H-F., Takacs, L., and Durum, S. K. Direct evidence for an intracellular role for tumor necrosis factor-α. Microinjection of tumor necrosis factor kills target cells. J. Immunol., 144: 162-169, 1990.
35. Bartsch, H., Pfizenmaier, K., Schroeder, M., and Nagel, G Intralesional application of recombinant human tumor necrosis factor α induces local tumor regression in patients with advanced malignancies. Eur. J. Cancer Clin Oncol., 25: 287-297, 1989.
36. Lienard, D., Ewanlenko, P., Delmotte, J., Renard, N , and Lejeune, F. High-dose recombinant tumor necrosis factor alpha in combination with interferon of the limbs for melanoma and sarcoma. J. Clin Oncol., 10: 52-57, 1992.